{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T04:38:06Z","timestamp":1782362286377,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T00:00:00Z","timestamp":1737849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T00:00:00Z","timestamp":1737849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"DOI":"10.1186\/s41927-025-00460-8","type":"journal-article","created":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T04:47:29Z","timestamp":1737866849000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A rare intersection: squamous cell carcinoma of the tonsil and the anti-TIF1 syndrome masquerade"],"prefix":"10.1186","volume":"9","author":[{"given":"Manush","family":"Sondhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Lear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleha","family":"Dar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madiha","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,26]]},"reference":[{"key":"460_CR1","doi-asserted-by":"publisher","unstructured":"Qiang JK, Kim WB, Baibergenova A, Alhusayen R. Risk of malignancy in dermatomyositis and polymyositis. J Cutan Med Surg. 2017 Mar\/Apr;21(2):131\u20136. https:\/\/doi.org\/10.1177\/1203475416665601. Epub 2016 Aug 20. PMID: 27534779.","DOI":"10.1177\/1203475416665601"},{"key":"460_CR2","doi-asserted-by":"publisher","unstructured":"Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med. 2001;134(12):1087\u201395. https:\/\/doi.org\/10.7326\/0003-4819-134-12-200106190-00008. PMID: 11412048.","DOI":"10.7326\/0003-4819-134-12-200106190-00008"},{"issue":"1","key":"460_CR3","doi-asserted-by":"publisher","first-page":"4545","DOI":"10.1038\/s41598-021-83729-5","volume":"11","author":"JL Hsu","year":"2021","unstructured":"Hsu JL, Liao MF, Chu CC, Kuo HC, Lyu RK, Chang HS, Chen CM, Wu YR, Chang KH, Weng YC, Chang CW, Chiang HI, Cheng CK, Lee PW, Huang CC, Ro LS. Reappraisal of the incidence, various types and risk factors of malignancies in patients with dermatomyositis and polymyositis in Taiwan. Sci Rep. 2021;11(1):4545. https:\/\/doi.org\/10.1038\/s41598-021-83729-5. PMID: 33633147; PMCID: PMC7907377.","journal-title":"Sci Rep"},{"issue":"2","key":"460_CR4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s12016-022-08922-4","volume":"63","author":"M Marz\u0119cka","year":"2022","unstructured":"Marz\u0119cka M, Niemczyk A, Rudnicka L. Autoantibody markers of increased risk of malignancy in patients with Dermatomyositis. Clin Rev Allergy Immunol. 2022;63(2):289\u201396. https:\/\/doi.org\/10.1007\/s12016-022-08922-4. Epub 2022 Feb 11. PMID: 35147864; PMCID: PMC9464248.","journal-title":"Clin Rev Allergy Immunol"},{"key":"460_CR5","doi-asserted-by":"publisher","unstructured":"Best M, Molinari N, Chasset F, Vincent T, Cordel N, Bessis D. Use of anti-transcriptional intermediary factor-1 Gamma autoantibody in identifying adult dermatomyositis patients with cancer: a systematic review and meta-analysis. Acta Derm Venereol. 2019;99(3):256\u2013262. https:\/\/doi.org\/10.2340\/00015555-3091. PMID: 30460368.","DOI":"10.2340\/00015555-3091"},{"issue":"11","key":"460_CR6","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1002\/art.38093","volume":"65","author":"DF Fiorentino","year":"2013","unstructured":"Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL, Rosen A, Casciola-Rosen L. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3. Arthritis Rheum. 2013;65(11):2954\u201362. https:\/\/doi.org\/10.1002\/art.38093. PMID: 24037894; PMCID: PMC4073292.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"460_CR7","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/rheumatology\/key357","volume":"58","author":"A Oldroyd","year":"2019","unstructured":"Oldroyd A, Sergeant JC, New P, McHugh NJ, Betteridge Z, Lamb JA, Ollier WE, Cooper RG, Chinoy H, UKMyoNet. The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis. Rheumatology (Oxford). 2019;58(4):650\u20135. https:\/\/doi.org\/10.1093\/rheumatology\/key357. PMID: 30535395; PMCID: PMC6434375.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"460_CR8","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.jaad.2007.06.027","volume":"57","author":"D Fiorentino","year":"2007","unstructured":"Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2007;57(6):929\u201337. https:\/\/doi.org\/10.1016\/j.jaad.2007.06.027.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"460_CR9","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1007\/s10067-022-06170-7","volume":"41","author":"H Yang","year":"2022","unstructured":"Yang H, Yan T, Zhang X, Sun W, Liu L, Du Y, Xue J. Clinical significance of anti-transcriptional intermediary factor 1-\u03b3 antibody in patients with dermatomyositis: a monocentric cross-sectional study. Clin Rheumatol. 2022;41(8):2439\u201348. https:\/\/doi.org\/10.1007\/s10067-022-06170-7. Epub 2022 Apr 14. PMID: 35422109.","journal-title":"Clin Rheumatol"},{"issue":"8","key":"460_CR10","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1002\/art.40895","volume":"71","author":"A Aussy","year":"2019","unstructured":"Aussy A, Fr\u00e9ret M, Gallay L, Bessis D, Vincent T, Jullien D, Drouot L, Jouen F, Joly P, Marie I, Meyer A, Sibilia J, Bader-Meunier B, Hachulla E, Hamidou M, Hu\u00eb S, Charuel JL, Fabien N, Viailly PJ, Allenbach Y, Benveniste O, Cordel N, Boyer O, OncoMyositis Study Group. The IgG2 isotype of Anti-transcription intermediary factor 1\u03b3 autoantibodies is a biomarker of Cancer and Mortality in Adult Dermatomyositis. Arthritis Rheumatol. 2019;71(8):1360\u201370. https:\/\/doi.org\/10.1002\/art.40895. Epub 2019 Jul 8. PMID: 30896088.","journal-title":"Arthritis Rheumatol"},{"key":"460_CR11","doi-asserted-by":"publisher","unstructured":"Cordel N, Dechelotte B, Jouen F, Lamb JA, Chinoy H, New P, Vencovsky J, Mann H, Galindo-Feria AS, Dani L, Selva-O\u2019Callaghan A, Werth VP, Ravishankar A, Landon-Cardinal O, Tressi\u00e8res B, Boyer O. Anti-transcription intermediary factor 1-gamma IgG2 isotype is associated with cancer in adult dermatomyositis: an ENMC multinational study. Rheumatology (Oxford). 2023;62(4):1711\u20131715. https:\/\/doi.org\/10.1093\/rheumatology\/keac577. PMID: 36250907.","DOI":"10.1093\/rheumatology\/keac577"},{"key":"460_CR12","unstructured":"Ogawa-Momohara M, Muro Y, Mitsuma T, Katayama M, Yanaba K, Nara M, Kakeda M, Kono M, Akiyama M. Strong correlation between cancer progression and anti-transcription intermediary factor 1\u03b3 antibodies in dermatomyositis patients. Clin Exp Rheumatol 2018 Nov-Dec;36(6):990\u20135. Epub 2018 May 8. PMID: 29745874."},{"issue":"11","key":"460_CR13","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1111\/ddg.14566_g","volume":"19","author":"J Lauinger","year":"2021","unstructured":"Lauinger J, Ghoreschi K, Volc S. Charakteristika Von Dermatomyositis-Patienten mit und ohne Malignom-Assoziation. J Der Deutschen Dermatologischen Gesellschaft = J German Soc Dermatology: JDDG. 2021;19(11):1601\u201312. https:\/\/doi.org\/10.1111\/ddg.14566_g.","journal-title":"J Der Deutschen Dermatologischen Gesellschaft = J German Soc Dermatology: JDDG"},{"issue":"7","key":"460_CR14","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.3390\/jcm11071925","volume":"11","author":"Y Harada","year":"2022","unstructured":"Harada Y, Tominaga M, Iitoh E, Kaieda S, Koga T, Fujimoto K, Chikasue T, Obara H, Kakuma T, Ida H, Kawayama T, Hoshino T. Clinical characteristics of Anti-TIF-1\u03b3 antibody-positive Dermatomyositis Associated with Malignancy. J Clin Med. 2022;11(7):1925. https:\/\/doi.org\/10.3390\/jcm11071925.","journal-title":"J Clin Med"},{"key":"460_CR15","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12016-015-8496-5","volume":"51","author":"Y Muro","year":"2016","unstructured":"Muro Y, Sugiura K, Akiyama M. Cutaneous manifestations in Dermatomyositis: key clinical and serological Features\u2014a Comprehensive Review. Clin Rev Allerg Immunol. 2016;51:293\u2013302. https:\/\/doi.org\/10.1007\/s12016-015-8496-5.","journal-title":"Clin Rev Allerg Immunol"},{"issue":"3","key":"460_CR16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1212\/WNL.0000000000002863","volume":"87","author":"A Hida","year":"2016","unstructured":"Hida A, Yamashita T, Hosono Y, Inoue M, Kaida K, Kadoya M, Miwa Y, Yajima N, Maezawa R, Arai S, Kurasawa K, Ito K, Shimada H, Iwanami T, Sonoo M, Hatanaka Y, Murayama S, Uchibori A, Chiba A, Aizawa H, Shimizu J. Anti-TIF1-\u03b3 antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology. 2016;87(3):299\u2013308. https:\/\/doi.org\/10.1212\/WNL.0000000000002863.","journal-title":"Neurology"},{"issue":"3","key":"460_CR17","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jaad.2014.12.009","volume":"72","author":"DF Fiorentino","year":"2015","unstructured":"Fiorentino DF, Kuo K, Chung L, Zaba L, Li S, Casciola-Rosen L. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1\u03b3 antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72(3):449\u201355. https:\/\/doi.org\/10.1016\/j.jaad.2014.12.009. Epub 2015 Jan 14. PMID: 25595720; PMCID: PMC4351728.","journal-title":"J Am Acad Dermatol"},{"key":"460_CR18","doi-asserted-by":"publisher","unstructured":"Chua CG, Low JZ, Lim WY, Manghani M. Characteristics of anti-transcriptional intermediary factor 1 gamma autoantibody-positive dermatomyositis patients in Singapore. Ann Acad Med Singap. 2022;51(12):755\u2013765. https:\/\/doi.org\/10.47102\/annals-acadmedsg.2022278. PMID: 36592144.","DOI":"10.47102\/annals-acadmedsg.2022278"},{"key":"460_CR19","doi-asserted-by":"publisher","unstructured":"Dalakas MC. Inflammatory myopathies: management of steroid resistance. Curr Opin Neurol. 2011;24(5):457\u2013\u200962. https:\/\/doi.org\/10.1097\/WCO.0b013e32834a9589. PMID: 21799409.","DOI":"10.1097\/WCO.0b013e32834a9589"},{"issue":"1","key":"460_CR20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.autrev.2011.06.007","volume":"11","author":"I Marie","year":"2011","unstructured":"Marie I, Mouthon L. Therapy of polymyositis and dermatomyositis. Autoimmun Rev. 2011;11(1):6\u201313. https:\/\/doi.org\/10.1016\/j.autrev.2011.06.007. Epub 2011 Jun 28. PMID: 21740984.","journal-title":"Autoimmun Rev"},{"key":"460_CR21","doi-asserted-by":"publisher","first-page":"102257","DOI":"10.1016\/j.coph.2022.102257","volume":"65","author":"S Moghadam-Kia","year":"2022","unstructured":"Moghadam-Kia S, Oddis CV. Current and new targets for treating myositis. Curr Opin Pharmacol. 2022;65:102257. https:\/\/doi.org\/10.1016\/j.coph.2022.102257. Epub 2022 Jun 17. PMID.","journal-title":"Curr Opin Pharmacol"},{"key":"460_CR22","doi-asserted-by":"publisher","unstructured":"Aggarwal R, Oddis CV. Therapeutic approaches in myositis. Curr Rheumatol Rep. 2011;13(3):182\u201391. https:\/\/doi.org\/10.1007\/s11926-011-0172-z. PMID: 21365210.","DOI":"10.1007\/s11926-011-0172-z"},{"issue":"24","key":"460_CR23","doi-asserted-by":"publisher","first-page":"e29108","DOI":"10.1097\/MD.0000000000029108","volume":"101","author":"L Lian","year":"2022","unstructured":"Lian L, Li M, Li Y, Wang K, Xu S. Combination therapy of tacrolimus, high doses of glucocorticosteroids, and cyclophosphamide against existing historical treatment for patients in severe conditions of interstitial lung diseases complicated with dermatomyositis: a retrospective analysis. Med (Baltim). 2022;101(24):e29108. https:\/\/doi.org\/10.1097\/MD.0000000000029108. PMID: 35713427; PMCID: PMC9276089.","journal-title":"Med (Baltim)"},{"issue":"3","key":"460_CR24","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/art.41105","volume":"72","author":"H Tsuji","year":"2020","unstructured":"Tsuji H, Nakashima R, Hosono Y, Imura Y, Yagita M, Yoshifuji H, Hirata S, Nojima T, Sugiyama E, Hatta K, Taguchi Y, Katayama M, Tanizawa K, Handa T, Uozumi R, Akizuki S, Murakami K, Hashimoto M, Tanaka M, Ohmura K, Mimori T. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, Tacrolimus, and Cyclophosphamide in interstitial lung diseases accompanied by Anti-melanoma differentiation-Associated Gene 5-Positive Dermatomyositis. Arthritis Rheumatol. 2020;72(3):488\u201398. https:\/\/doi.org\/10.1002\/art.41105. Epub 2020 Jan 27. PMID: 31524333.","journal-title":"Arthritis Rheumatol"},{"key":"460_CR25","doi-asserted-by":"publisher","unstructured":"Ly NTM, Ma N, Ueda-Hayakawa I, Nguyen CTH, Anada R, Okamoto H, Fujimoto M. Clinical and laboratory parameters predicting cancer in dermatomyositis patients with anti-TIF1\u03b3 antibodies. J Dermatol Sci. 2021;104(3):177\u2013184. https:\/\/doi.org\/10.1016\/j.jdermsci.2021.10.003. Epub 2021 Oct 13. Erratum in: J Dermatol Sci. 2022;107(1):56. https:\/\/doi.org\/10.1016\/j.jdermsci.2022.06.003. PMID: 34772582.","DOI":"10.1016\/j.jdermsci.2021.10.003 10.1016\/j.jdermsci.2022.06.003"},{"issue":"1","key":"460_CR26","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1002\/hed.23703","volume":"37","author":"AH Adi","year":"2015","unstructured":"Adi AH, Alturkmani H, Spock T, Williams Yohannes P, Wargo S, Szabo E, Gutkind JS, Van Waes C. Dermatomyositis paraneoplastic syndrome before symptomatic tonsillar squamous cell carcinoma: a case report. Head Neck. 2015;37(1):E1\u20133. https:\/\/doi.org\/10.1002\/hed.23703. Epub 2014 Jun 27. PMID: 24715579.","journal-title":"Head Neck"},{"issue":"4","key":"460_CR27","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3349\/ymj.2010.51.4.605","volume":"51","author":"SW Kim","year":"2010","unstructured":"Kim SW, Shim JS, Eun YG, Kwon KH. Tonsillar squamous cell carcinoma associated with dermatomyositis: the first 2 cases in Korea. Yonsei Med J. 2010;51(4):605\u20138. https:\/\/doi.org\/10.3349\/ymj.2010.51.4.605. PMID: 20499432; PMCID: PMC2880279.","journal-title":"Yonsei Med J"},{"issue":"6","key":"460_CR28","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00296-003-0319-y","volume":"23","author":"C Botsios","year":"2003","unstructured":"Botsios C, Ostuni P, Boscolo-Rizzo P, Da Mosto MC, Punzi L, Marchiori C. Dermatomyositis and malignancy of the pharynx in caucasian patients: report of two observations. Rheumatol Int. 2003;23(6):309\u201311. https:\/\/doi.org\/10.1007\/s00296-003-0319-y. Epub 2003 Jun 28. PMID: 12838366.","journal-title":"Rheumatol Int"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00460-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-025-00460-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00460-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T04:47:32Z","timestamp":1737866852000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcrheumatol.biomedcentral.com\/articles\/10.1186\/s41927-025-00460-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,26]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["460"],"URL":"https:\/\/doi.org\/10.1186\/s41927-025-00460-8","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,26]]},"assertion":[{"value":"17 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required for a case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent for publication of identifying images or other personal or clinical details was obtained from the next of kin.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}